logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Amivantamab for advanced non-small-cell lung cancer

< Back

Amivantamab for advanced non-small-cell lung cancer

Drugs

Cancer and Palliative Care

August 2021


Amivantamab is in clinical development in the treatment of patients with advanced non-small-cell lung cancer (NSCLC) who have previously been treated with platnum-based chemotherapy. NSCLC makes up the majority of lung cancers in the UK. Metastatic NSCLC is when the cancer has spread beyond the lung that was initially affected, most often to the liver, the adrenal glands, the bones, and the brain. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable.
Amivantamab is an intravenously administered drug that can bind to both EGFR and another receptor that helps tumours grow, hepatocyte growth factor receptor (cMet). Binding to these receptors slows tumour growth by stopping them receiving signals and making them a target to be brokendown and destroyed by for immune cells. If licenced amivantamab will provide a treatment for patients with advanced NSCLC who have previously been treated with platnum-based chemotherapy, who have limited therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts